Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Obesity
Biotech
iBio champions AI-fueled obesity pivot as 1st asset hits clinic
Upon finally reaching the clinic, iBio feels vindicated about the artificial intelligence-powered discovery platform it picked up in 2022.
Fraiser Kansteiner
Jun 26, 2026 5:00am
Corxel touts ‘competitive’ ph. 2 results for oral GLP-1 asset
Jun 23, 2026 8:00am
Fierce Pharma
Novo Nordisk’s ‘optimistic’ CEO Doustdar sits down with Fierce
Jun 11, 2026 7:00am
ADA: Novo CSO says ‘jury still out’ on CagriSema v. retatrutide
Jun 10, 2026 11:10am
ADA: Tolerability questions linger for Boehringer's obesity drug
Jun 8, 2026 4:30am
ADA: Roche, Zealand make tolerability case for petrelintide
Jun 7, 2026 3:00am
